- NetraMark Solutions (CSE:AIAI) has appointed industry veteran Jeff Huntsman to its strategic advisory board
- The generative artificial intelligence software developer in clinical trial analytics intends to benefit from his experience with strategic and tactical commercial planning, global business development, building and growing commercial operations
- His career spans more than three decades, and he was previously the chief commercial officer at Sitero, Citeline, ConnectiveRx and LIQUENT
- Shares of NetraMark Holdings last traded at $0.26
NetraMark Solutions (CSE:AIAI) has appointed industry veteran Jeff Huntsman to its strategic advisory board.
The generative artificial intelligence (AI) software developer in clinical trial analytics intends to benefit from his experience with strategic and tactical commercial planning, global business development, building and growing commercial operations, mergers, divestiture and acquisition activities. His career spans more than three decades, and he is the president at J-Boys Consulting where he provides advice to private equity, venture capital and emerging growth companies.
He was previously the chief commercial officer at Sitero, Citeline, ConnectiveRx, and LIQUENT. He has also held executive leadership roles at Parexel, Thomson Reuters, Rogers Communications and previously served as a Health Care Advisor at Warburg Pincus and Growth Capital Partners.
The plan is that his addition to the advisory board will further strengthen the company’s ability to deliver its AI-based offerings and drive business growth.
“We are honored to welcome Jeff to our advisory board. His experience and expertise in the pharmaceutical industry will help NetraMark further develop its commercialization strategies,” George Achilleos, CEO of NetraMark Holdings, said in a statement.
Based out of Toronto, NetraMark Holdings is focused on the development of generative artificial Intelligence and machine learning solutions for the pharmaceutical industry.
The company recently launched NetraAI Lab, which can enable biopharmaceutical companies to apply NetraAI to their data rapidly and cost effectively. What separates NetraAI Lab from other lab-based AI solutions is it includes focus mechanisms that separate small datasets into explainable and unexplainable subsets. The company added that the platform has the capability of identifying the most important variables in small data sets, including those from a single Phase 2 trial that will help clinical trial teams in making better decisions.
Shares of NetraMark Holdings last traded at $0.26.
Join the discussion: Find out what everybody’s saying about this stock on the NetraMark Holdings Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
